StockNews.com Initiates Coverage on BioLineRx (NASDAQ:BLRX)

StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX) in a research note issued to investors on Thursday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reduced their price target on shares of BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BLRX stock opened at $0.22 on Thursday. The stock has a fifty day moving average price of $0.35 and a 200 day moving average price of $0.54. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The stock has a market cap of $17.91 million, a PE ratio of -1.02 and a beta of 1.39. BioLineRx has a 1 year low of $0.19 and a 1 year high of $1.64.

Institutional Trading of BioLineRx

Large investors have recently added to or reduced their stakes in the stock. PVG Asset Management Corp acquired a new stake in shares of BioLineRx in the second quarter valued at about $70,000. Atria Investments Inc raised its stake in shares of BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock valued at $72,000 after purchasing an additional 29,193 shares during the period. Finally, CVI Holdings LLC acquired a new position in shares of BioLineRx during the second quarter worth $462,000. 1.56% of the stock is currently owned by institutional investors and hedge funds.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.